Skip to main content

Maze Therapeutics

Maze Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on translating human genetics into precision small molecule medicines for kidney and metabolic diseases. The company utilizes its proprietary Compass platform to advance clinical pipeline candidates targeting APOL1-mediated kidney disease, Pompe disease, and chronic metabolic conditions. Principal revenue is derived from development milestone payments, strategic research collaborations, and licensing partnerships with global pharmaceutical companies. Core end markets encompass nephrology treatment clinics, genetic disease specialists, and biopharmaceutical partners globally. Maze Therapeutics holds an innovative position in the biopharmaceutical sector for genetically validated target discovery and precision small molecule therapeutics. The company is headquartered in South San Francisco, California, operating as a private biotechnology corporation.

2 of the funds FundTelligence covers report a position in Maze Therapeutics.

Legal name
MAZE THERAPEUTICS
Sector
Health Care
Country
United States
Funds holding it
2

Funds holding Maze Therapeutics

Loading...